HGS Calls For Confidence In Slow, Steady Ramp-Up For Benlysta
This article was originally published in The Pink Sheet Daily
In the fourth quarter, the new SLE drug continued its slow sales growth – HGS said rheumatologists are still largely in trial mode, testing the drug in a few patients and gaining confidence in its benefits.
You may also be interested in...
Benlysta In GSK’s Hands: A Slow-but-steady Launch, Or A Dud?
With GlaxoSmithKline and Human Genome Sciences agreeing to a merger July 16, the key question for the multinational pharma becomes what it will do to strengthen sales for Benlysta, a lupus drug launched in 2011 that has fallen short of bullish commercial expectations.
GSK Will Take Its HGS Bid Hostile; Will Shareholders Buy In?
GSK plans to take its $13 per share offer straight to Human Genome Sciences shareholders after being turned down by the company last month.
GSK And HGS Face Off Over Buyout
Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.